Diana Restifo

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 2

Top Topics

Ejection Fraction

Top Venues

Molecular cancer therapeutics

bioRxiv : the preprint server for biology

This page only lists publications with an associated author ORCID identifier.

Publications

Charline Ogier, Akino Mercy Charles Solomon, Zhen Lu, Ludmila Recoules, Alena Klochkova, Linara Gabitova-Cornell, Battuya Bayarmagnai, Diana Restifo, Aizhan Surumbayeva, Debora Barbosa Vendramini-Costa, Alexander Y Deneka, Ralph Francescone, Anna C Lilly, Alyssa Sipman, Jaye C Gardiner, Tiffany Q Luong, Janusz Franco-Barraza, Nina Ibeme, Kathy Q Cai, Margret B Einarson, Emmanuelle Nicolas, Andrei Efimov, Emily Megill, Nathaniel W Snyder, Corinne Bousquet, Jerome Cros, Yunyun Zhou, Erica A Golemis, Bojana Gligorijevic, Jonathan Soboloff, Serge Y Fuchs, Edna Cukierman, Igor Astsaturov
Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6). bioRxiv : the preprint server for biology (2023)
Diana Restifo, Joseph R McDermott, Dusica Cvetkovic, Troy Dos Santos, Charline Ogier, Aizhan Surumbayeva, Elizabeth A Handorf, Caleb Schimke, C-M Charlie Ma, Kathy Q Cai, Anthony J Olszanski, Umesh Kathad, Kishor Bhatia, Panna Sharma, Aditya Kulkarni, Igor Astsaturov
Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies. Molecular cancer therapeutics (2023)